Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $262.54 | 16 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $88.46 | 5 | $0 (2022) |
| Merck Sharp & Dohme LLC | $41.16 | 3 | $0 (2022) |
| Novo Nordisk Inc | $30.07 | 2 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $26.08 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $24.99 | 1 | $0 (2022) |
| GlaxoSmithKline, LLC. | $21.81 | 1 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.99 | 1 | $0 (2021) |
| Lilly USA, LLC | $12.98 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $154.92 | 9 | ABBVIE INC. ($76.30) |
| 2021 | $107.62 | 7 | Novo Nordisk Inc ($30.07) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2022 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 09/15/2022 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/12/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: Diabetes | ||||||
| 09/09/2022 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/10/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.24 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2022 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 04/29/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: NEUROSCIENCE | ||||||
| 04/21/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.16 | General |
| Category: NEUROSCIENCE | ||||||
| 11/09/2021 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Obesity | ||||||
| 07/09/2021 | Merck Sharp & Dohme Corporation | BELSOMRA (Drug), JANUVIA, JANUMET | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: NEUROSCIENCE | ||||||
| 02/06/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Diabetes | ||||||
| 01/26/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: RESPIRATORY | ||||||
| 01/14/2021 | Merck Sharp & Dohme Corporation | BELSOMRA (Drug), JANUVIA, JANUMET | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 190 | 212 | $25,085 | $8,897 |
| 2022 | 5 | 269 | 455 | $45,182 | $19,783 |
| 2021 | 6 | 205 | 287 | $31,008 | $14,643 |
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 76 | $11,020 | $2,739 | 24.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 26 | 26 | $4,720 | $2,579 | 54.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 39 | 39 | $5,265 | $2,273 | 43.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 30 | $2,850 | $737.11 | 25.9% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 25 | 25 | $750.00 | $347.25 | 46.3% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 16 | 16 | $480.00 | $222.24 | 46.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 101 | 213 | $30,885 | $14,325 | 46.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 111 | $10,545 | $4,681 | 44.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 39 | 57 | $2,280 | $385.57 | 16.9% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 31 | 42 | $672.00 | $280.88 | 41.8% |
| 81002 | Urinalysis, manual test | Office | 2022 | 22 | 32 | $800.00 | $109.90 | 13.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 107 | $15,515 | $7,334 | 47.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 81 | 125 | $11,875 | $6,197 | 52.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $2,365 | $841.76 | 35.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 18 | 18 | $720.00 | $131.55 | 18.3% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 13 | 13 | $208.00 | $93.83 | 45.1% |
| 81002 | Urinalysis, manual test | Office | 2021 | 12 | 13 | $325.00 | $45.24 | 13.9% |
About Brandy Martisek, NP
Brandy Martisek, NP is a Family healthcare provider based in Magnolia, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2020. The National Provider Identifier (NPI) number assigned to this provider is 1770192791.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brandy Martisek, NP has received a total of $262.54 in payments from pharmaceutical and medical device companies, with $154.92 received in 2022. These payments were reported across 16 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($262.54).
As a Medicare-enrolled provider, Martisek has provided services to 664 Medicare beneficiaries, totaling 954 services with total Medicare billing of $43,323. Data is available for 3 years (2021–2023), covering 17 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Magnolia, AR
- Active Since 07/26/2020
- Last Updated 06/15/2023
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1770192791
Products in Payments
- VRAYLAR (Drug) $74.94
- BELSOMRA (Drug) $26.59
- LEQVIO (Drug) $24.99
- TRELEGY ELLIPTA (Drug) $21.81
- TRINTELLIX (Drug) $16.99
- Wegovy (Drug) $16.36
- VERQUVO (Drug) $14.57
- Ozempic (Drug) $13.71
- TOUJEO (Biological) $13.58
- QULIPTA (Drug) $13.52
- MOUNJARO (Drug) $12.98
- SOLIQUA 100/33 (Biological) $12.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Magnolia
Mrs. Cheryl Wirth, Rn,Fnp-Bc, RN,FNP-BC
Family — Payments: $10,302
Jerod Mckeehan, Fnp-C, FNP-C
Family — Payments: $7,303
Mrs. Shawntel Price, Aprn, APRN
Family — Payments: $4,451
Mrs. Andrea Spurling, Apn, APN
Family — Payments: $3,141
Samantha Jih, Fnp-C, FNP-C
Family — Payments: $3,120
Melody Minnick
Family — Payments: $1,898